Daewoong Pharma Total Liabilities
Daewoong Pharma total liabilities. Based on the latest financial reports, Daewoong Pharma (069620) has total liabilities worth ₩1.26 Trillion KRW (≈ $851.43 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Daewoong Pharma asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Daewoong Pharma (2007–2024)
Total liabilities of Daewoong Pharma from 2007 to 2024. This chart illustrates how Daewoong Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Daewoong Pharma's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Daewoong Pharma Competitors by Total Liabilities
The table below lists competitors of Daewoong Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Anoky Group
SHE:300067
|
China | CN¥1.03 Billion |
|
Fujian Yuanli Active Carbon Co Ltd
SHE:300174
|
China | CN¥789.31 Million |
|
Limin Chemical Co Ltd
SHE:002734
|
China | CN¥2.52 Billion |
|
Thai Vegetable Oil Public Company Limited
BK:TVO
|
Thailand | ฿3.48 Billion |
|
Qiming Information Technology Co Ltd
SHE:002232
|
China | CN¥465.75 Million |
|
Shanghai Huitong Energy Co Ltd
SHG:600605
|
China | CN¥91.03 Million |
|
Ardmore Shpng
NYSE:ASC
|
USA | $154.39 Million |
|
Qt Group Oyj
HE:QTCOM
|
Finland | €57.63 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Daewoong Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Daewoong Pharma assets under control.
Liquidity & Leverage Metrics
Daewoong Pharma Total Liabilities Ratios Explained
Daewoong Pharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daewoong Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daewoong Pharma (2007–2024)
The table below shows the annual total liabilities of Daewoong Pharma from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩1.05 Trillion ≈ $711.56 Million |
+37.65% |
| 2023-12-31 | ₩762.77 Billion ≈ $516.92 Million |
-7.22% |
| 2022-12-31 | ₩822.12 Billion ≈ $557.14 Million |
+15.34% |
| 2021-12-31 | ₩712.77 Billion ≈ $483.04 Million |
+6.12% |
| 2020-12-31 | ₩671.66 Billion ≈ $455.17 Million |
+10.15% |
| 2019-12-31 | ₩609.75 Billion ≈ $413.22 Million |
+1.62% |
| 2018-12-31 | ₩600.04 Billion ≈ $406.64 Million |
+3.10% |
| 2017-12-31 | ₩581.99 Billion ≈ $394.40 Million |
+7.75% |
| 2016-12-31 | ₩540.15 Billion ≈ $366.05 Million |
+48.28% |
| 2015-12-31 | ₩364.29 Billion ≈ $246.87 Million |
+52.58% |
| 2014-12-31 | ₩238.76 Billion ≈ $161.80 Million |
+69.27% |
| 2013-12-31 | ₩141.05 Billion ≈ $95.59 Million |
+47.30% |
| 2012-12-31 | ₩95.76 Billion ≈ $64.89 Million |
-29.61% |
| 2011-12-31 | ₩136.04 Billion ≈ $92.20 Million |
-34.40% |
| 2008-12-31 | ₩207.39 Billion ≈ $140.55 Million |
+68.28% |
| 2007-12-31 | ₩123.24 Billion ≈ $83.52 Million |
-- |
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more